Boston BioCom was created to take advantage of unique access to exceptional scientific advances in both the U.S. and Russia and to manage a hand-picked portfolio of biomedical innovations towards optimal commercial endpoints. The company brings together the preeminent academic research and development expertise of Harvard and its Partners affiliated hospitals Massachusetts General and Brigham & Women's, Pfizer's industry-leading pharmaceutical capabilities and guidance, and a highly experienced management team to create value from an extraordinary flow of technology opportunities. The company is driven by its goals of making a major impact on global health and addressing multi-billion dollar markets with successful companies created around its breakthrough science.

Boston BioCom will accomplish this by developing the best of both Russian and U.S. biotechnologies in Harvard laboratories with the guidance of one of the world's preeminent pharmaceutical companies. The company is currently engaged in multiple collaborative programs with innovative scientists from research institutes, pharmaceutical companies, and biotech companies from both countries. In essence, it is the first company aimed at synergistic development of innovations from both countries for global markets, with the aim of also bringing benefit to Russia.

This approach originated in 2003 when the U.S. Department of State engaged a team from the Center for the Integration of Medicine and Innovative Technology (CIMIT) - a consortium of Harvard Medical School, Massachusetts Institute of Technology and other Boston institutes - to canvass the Russian biomedical research community and identify technologies from selected institutions that had potential for commercial development and application so they could be preferentially supported.

The CIMIT Russia team found remarkable bioscience advances that had significant market potential and addressed serious unmet medical needs. This team was able to leverage its scientific network at CIMIT, Massachusetts General Hospital (MGH), the largest Harvard teaching/research hospital, Harvard Medical School and Partners to validate these findings and develop them further. In some cases, original research from Partners HealthCare institutions were integrated with Russian discoveries to generate new and even more innovative technologies. The commercial potential of this synergistic dynamic created the impetus to form Boston BioCom.

Members from the original CIMIT Russia team, together with a number of business professionals, worked with Partners HealthCare to form Boston BioCom in late 2007 in conjunction with an initial capital investment of $10 million from Pfizer Inc.